News
Barfresh Reports 11% Revenue Gain in Q2
Barfresh Food Group (NASDAQ:BRFH), a provider of ready-to-drink and frozen beverage products often found in schools and institutional settings, released earnings for the second quarter of fiscal
Lumentum Q4 Revenue and Margins Surge
Lumentum(NASDAQ:LITE) reported fourth quarter fiscal 2025 results on August 12, 2025, with non-GAAP revenue of $480.7 million and non-GAAP EPS of $0.88, both exceeding the high end of guidance. The
Spectral Ai Posts 32% Revenue Drop in Q2
Spectral Ai (NASDAQ:MDAI), a medical technology company specializing in wound care diagnostics, reported its second quarter 2025 results on August 13, 2025. The big news of the release was the
Intellinetics Sales Down 13.6 Percent
Intellinetics (NYSEMKT:INLX), a provider of document management and digital transformation software, released its results on August 13, 2025. The most notable developments were a
Kodiak Sciences Beats Q2 Loss Estimates
Kodiak Sciences (NASDAQ:KOD), a biotechnology company specializing in retinal disease therapies, released its Q2 2025 earnings results on August 13, 2025. The most notable news: the company reported
SKYX Platforms Revenue Jumps 8% in Q2
SKYX Platforms (NASDAQ:SKYX), a developer of advanced smart-home and safety platform technologies, released its earnings for the second quarter of fiscal 2025 on August 12, 2025. Gross profit (GAAP)
Urban One Reports 22% Revenue Drop in Q2
Urban One (NASDAQ:UONE), a media company focused on serving African-American and urban audiences, reported Q2 fiscal 2025 results on August 13, 2025. The report highlighted a significant
Lumentum Revenue Jumps 56 Percent in Q4
Lumentum (NASDAQ:LITE), a maker of optical and photonic components for cloud, networking, and industrial applications, released its fiscal fourth-quarter results on August 12, 2025. The key news
Ieh Posts 11 Percent Revenue Drop in Q1
IEH (OTC:IEHC), a specialty electronic connector manufacturer serving the military, aerospace, and industrial markets, reported first quarter fiscal 2026 results on August 13, 2025. The report
Arcos Dorados Sales Reach $1.1 Billion
Arcos Dorados(NYSE:ARCO) reported second quarter 2025 results on August 13, 2025. Total revenue reached $1.1 billion, with systemwide comparable sales up 12.1% and adjusted EBITDA at $110.1 million
ProPhase Labs Posts Narrower Q2 Loss
ProPhase Labs (NASDAQ:PRPH), a diversified consumer healthcare and diagnostics company, posted its second-quarter 2025 results on August 13, 2025. The most notable news was a sharp shortfall in GAAP
Connect Biopharma Posts Q2 Revenue Drop
Connect Biopharma (NASDAQ:CNTB), a biotechnology company developing therapies for inflammatory diseases, released its second quarter 2025 earnings on August 13, 2025. The main highlight was a
Loar Posts 27 Percent Revenue Jump in Q2
Loar (NYSE:LOAR), an aerospace and defense supplier known for its proprietary components and strong aftermarket presence, released its second quarter earnings on August 13, 2025. The standout news
Moleculin Biotech Misses Fiscal Q2 EPS
Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 results on August 13, 2025.
The biggest news from this update was a
VerifyMe Beats Q2 Loss Revenue Drops 16%
VerifyMe (NASDAQ:VRME), a provider of logistics technology and authentication solutions for high-value and sensitive shipments, reported second quarter results on August 13, 2025. The company posted
LUCD Reports Results
Lucid Diagnostics (NASDAQ:LUCD), a diagnostics company focused on non-invasive detection of esophageal precancer and cancer, released its second quarter 2025 earnings results on August 13, 2025
Sbc Medical Group Posts Weak Fiscal Q2
Sbc Medical Group (NASDAQ:SBC), a provider of cosmetic and medical services with a broad franchise and technology platform, released its earnings for the second quarter of fiscal 2025 on August 13
Sanara MedTech Sales Jump 28 Percent
Sanara MedTech (NASDAQ:SMTI), a developer of surgical wound care products and value-based care technology, reported its Q2 FY2025 earnings on August 13, 2025. The report showed the company’s GAAP
PDSB Loss Improves as Costs Drop
PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for
This Legacy Stock Is Back, Poised for a Major Rebound
Retail stocks have been through a few tough years. The SPDR S&P Retail ETF (NYSEMKT: XRT) posted a total return of 12% over the last year, far behind the S&P 500 (SNPINDEX: ^GSPC) index's 19%
Performance Food Sales Jump 12 Percent
Performance Food Group (NYSE:PFGC), a leading foodservice distributor serving restaurants, convenience stores, vending, and more, reported financial results for Q4 FY2025 on August 13, 2025. The
Instil Bio Posts Wider Loss in Q2
Instil Bio (NASDAQ:TIL), a clinical-stage biotechnology company focused on developing immunotherapies for cancer, released its second quarter 2025 earnings on August 13, 2025. The report highlighted
Perspective Therapeutics Reports Q2 Loss
Perspective Therapeutics (NYSEMKT:CATX), a clinical-stage company focused on targeted radiopharmaceutical cancer therapies, reported results for Q2 2025 on August 13, 2025. The company posted GAAP
1 Green Flag for Cameco Stock Right Now
Cameco's (NYSE: CCJ) management styles the company as a "pure-play investment in the growing demand for nuclear energy," and with good reason. Its mix of uranium mining, nuclear fuel services, and
M-tron Industries Sales Jump 12 Percent
M-tron Industries (NYSEMKT:MPTI), a designer and manufacturer of frequency and spectrum control products for aerospace, defense, and high-reliability markets, released its earnings on August 12